This company has been marked as potentially delisted and may not be actively trading. NASDAQ:VBIV VBI Vaccines (VBIV) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About VBI Vaccines Stock (NASDAQ:VBIV) 30 days 90 days 365 days Advanced Chart Remove Ads Get VBI Vaccines alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.02▼$0.7952-Week Range N/AVolume29.90 million shsAverage Volume3.66 million shsMarket Capitalization$1.87 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewVBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.Read More… Remove Ads Receive VBIV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VBI Vaccines and its competitors with MarketBeat's FREE daily newsletter. Email Address VBIV Stock News HeadlinesVBI Vaccines Restructures and Acquired by K2 VBI TrustJanuary 3, 2025 | tipranks.comVBI Vaccines Issues Voluntary Nationwide Recall of all PreHevbrio Vaccine Due to Discontinuation of Company OperationsNovember 15, 2024 | businesswire.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 2, 2025 | Porter & Company (Ad)Why Is VBI Vaccines (VBIV) Stock Up 62% Today?August 6, 2024 | investorplace.comVBI Vaccines to be delisted from Nasdaq following restructuringAugust 4, 2024 | investing.comVBI Vaccines Provides an Update on its Restructuring ProceedingsAugust 3, 2024 | finance.yahoo.comVBI Vaccines secures court protection for restructuringAugust 1, 2024 | investing.comVBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic AlternativesJuly 30, 2024 | stockhouse.comSee More Headlines VBIV Stock Analysis - Frequently Asked Questions How were VBI Vaccines' earnings last quarter? VBI Vaccines Inc. (NASDAQ:VBIV) announced its earnings results on Monday, March, 13th. The biopharmaceutical company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($1.40) by $0.20. The biopharmaceutical company had revenue of $0.29 million for the quarter, compared to analysts' expectations of $1.98 million. VBI Vaccines had a negative net margin of 881.79% and a negative trailing twelve-month return on equity of 525.42%. When did VBI Vaccines' stock split? Shares of VBI Vaccines reverse split before market open on Wednesday, April 12th 2023. The 1-20 reverse split was announced on Wednesday, April 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of VBI Vaccines own? Based on aggregate information from My MarketBeat watchlists, some other companies that VBI Vaccines investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Pfizer (PFE) and Novavax (NVAX). Company Calendar Last Earnings3/13/2023Today4/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VBIV CIK764195 Webwww.vbivaccines.com Phone(617) 830-3031FaxN/AEmployees22Year Founded2001Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-92,840,000.00 Net Margins-881.79% Pretax Margin-881.79% Return on Equity-525.42% Return on Assets-45.87% Debt Debt-to-Equity RatioN/A Current Ratio0.34 Quick Ratio0.21 Sales & Book Value Annual Sales$9.41 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.32 per share Price / BookN/AMiscellaneous Outstanding Shares28,682,000Free Float25,713,000Market Cap$1.87 million OptionableOptionable Beta2.18 Social Links 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NASDAQ:VBIV) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTermination: 18F (read immediately)Have you ever heard of the government's 18F program? It helped manage digital services across the governmen...Altimetry | SponsoredPartner with Elon Musk on Project Colossus… Before May 1stEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VBI Vaccines Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VBI Vaccines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.